Owens & Minor (Richmond, Virginia) said that it has successfully completed its previously announced public offering of $275 million of 3.875% senior notes due 2021 and $275 million of 4.375% senior notes due 2024. The new notes were offered pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC).

The new notes are guaranteed on a senior unsecured basis by Owens & Minor Distribution, and Owens & Minor Medical, both wholly-owned subsidiaries of the company.

Owens & Minor intends to use the proceeds from the offering to fund its previously reported acquisition of Medical Action Industries (Brentwood, New York), to fund the redemption of all of its outstanding 6.35% senior notes due 2016 and for other general corporate purposes.

Owens & Minor also said that it has directed the trustee under the indenture governing the 2016 notes to issue notice of redemption to the holders of all outstanding 2016 Notes. All outstanding 2016 notes will be redeemed on Oct. 16, 2014 at a make-whole redemption price, calculated in accordance with the indenture governing the 2016 notes.

In other financing news;

Oxford Finance (Alexandria, Virginia), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, reported the closing of a $20 million senior secured term loan agreement with Pulmonx (Redwood City, California). Proceeds of the loan will be used to support the company's U.S. clinical trial of its Zephyr Endobronchial Valve used for the treatment of emphysema and to expand its business worldwide.

"Emphysema is a serious disease affecting millions of people globally," said Christopher A. Herr, managing director for Oxford Finance. "Pulmonx's Zephyr Endobronchial Valve is a highly effective therapy for the treatment of this debilitating disease. Oxford is pleased to provide financing to support Pulmonx's ongoing product development and marketing efforts, which will improve the lives of those suffering from emphysema."